As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey. Among these analysts, 17% recommended a “buy” or “strong buy” on the stock. 66% of the analysts have a “hold” recommendation on Teva Pharmaceutical Industries. The other 17% of the analysts provided a “sell” recommendation. The above chart shows analysts’ recommendation summary for Teva over the last few months.
As of October 11, Teva Pharmaceutical Industries stock has a consensus target price of $21.53 per share, which implies a return potential of 3.9% based on its closing price of $21.08 on October 10. Teva stock declined ~2.4% over the last week and ~0.7% yesterday due to the broader market sell-off. However, analysts remain positive on the stock’s growth prospects.
As of October 11, Pfizer (PFE), Novartis (NVS), and Mylan (MYL) have consensus target prices of $42.47, $98.50, and $45.18, respectively. The target prices imply 12-month return potentials of -4.6%, 16.7%, and 30.6%, respectively.